Table 2 Participants’ (a) perceptions of the impacts of HIV cure, (b) perception and attitudes towards HIV functional cure, and (c) consideration about HIV functional cure trial, by treatment status
Treatment-naïve (n = 153) (reference) | Treatment-experienced (n = 203) | |||||
|---|---|---|---|---|---|---|
n | % | n | % | OR (95% CI) | ||
(a) Perceived impacts of HIV cure | ||||||
No longer needing to take HIV medications | 62 | 40.5 | 97 | 48.3 | 1.37 (0.89–2.09) | |
Restoration and stabilization of effective immune function | 116 | 75.8 | 107 | 53.2 | 0.36 (0.23–0.58)*** | |
Not getting HIV for a second time | 20 | 13.1 | 33 | 16.4 | 1.31 (0.72–2.38) | |
No longer needing to visit a doctor for HIV | 28 | 18.3 | 68 | 33.8 | 2.28 (1.38–3.78)** | |
No longer at risk of AIDS or HIV-related morbidity | 71 | 46.4 | 70 | 34.8 | 0.62 (0.40–0.95)* | |
No longer be transmitting HIV to others | 95 | 62.1 | 105 | 52.2 | 0.67 (0.44–1.02) | |
Being considered as a person not living with HIV | 34 | 22.2 | 59 | 29.4 | 1.45 (0.89–2.37) | |
(b) Perception and attitude towards HIV functional cure | ||||||
Awareness of HIV functional cure | ||||||
Never heard about it | 94 | 62.3 | 109 | 54.0 | 1.00 | |
Heard but didn’t know the details | 21 | 13.9 | 71 | 35.1 | 2.92 (1.67–5.10)*** | |
Heard and understood what it is | 36 | 23.8 | 22 | 10.9 | 0.53 (0.29–0.96)* | |
Level of anticipation for HIV functional cure | ||||||
< 10 | 59 | 38.6 | 78 | 40.0 | 0.94 (0.61–1.45) | |
10 | 94 | 61.4 | 117 | 60.0 | 1.00 | |
Willingness in joining a functional cure trial | ||||||
Maybe/probably/definitely no | 10 | 6.5 | 16 | 7.9 | 0.82 (0.36–1.85) | |
Maybe/probably/definitely yes | 143 | 93.5 | 187 | 92.1 | 1.00 | |
(c) Considerations about HIV functional cure trial | ||||||
Important factors to be considered about the trial | ||||||
Safety of the therapy | 148 | 96.7 | 195 | 97.0 | 1.10 (0.33–3.67) | |
Duration of the clinical trial | 123 | 80.4 | 159 | 79.1 | 0.92 (0.55–1.56) | |
Incentives for participation | 40 | 26.1 | 40 | 20.3 | 0.72 (0.44–1.19) | |
Views and support from family and peers | 50 | 32.7 | 51 | 26.0 | 0.72 (0.46–1.15) | |
Advice from healthcare professionals | 139 | 174 | 90.8 | 87.0 | 0.67 (0.34–1.34) | |
Credibility of the research institution | 132 | 86.3 | 180 | 89.6 | 1.36 (0.72–2.60) | |
Interruption of HIV antiretroviral medications | 135 | 88.2 | 166 | 83.4 | 0.67 (0.36–1.24) | |
Concerns about consequences of joining a trial | ||||||
CD4 count going down | 118 | 77.1 | 143 | 71.9 | 0.76 (0.47–1.23) | |
HIV viral load going up | 132 | 86.3 | 163 | 81.5 | 0.70 (0.39–1.26) | |
Becoming infectious to the others | 123 | 80.4 | 147 | 73.9 | 0.69 (0.41–1.15) | |
Presence of AIDS or other related complications | 140 | 91.5 | 166 | 83.0 | 0.45 (0.23–0.89)* | |
Adverse effects of therapy | 127 | 83.0 | 161 | 80.5 | 0.85 (0.49–1.46) | |